Final results of a randomized phase 1b study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies Meeting Abstract


Authors: Picozzi, V. J.; Ramanathan, R. K.; Lowery, M. A.; Ocean, A. J.; Mitchell, E. P.; O'Neil, B. H.; Guarino, M. J.; Conkling, P. R.; Cohen, S. J.; Bahary, N.; Frank, R. C.; Dragovich, T.; Bridges, B. B.; Lee, M.; Korn, R. L.; Pandit-Taskar, N.; Goldsmith, S. J.; Intenzo, C. M.; Sheikh, A.; Manzone, T. C.; Miller, M. L.; Yu, M.; Joyce, J. M.; Strauss, E. B.; Passalaqua, S.; Dorn, R. V.; Anderson, M. J.; Holt, M.; Braiteh, F. S.; Lee, F. C.; Gribbin, T. E.; Richards, D. A.; Starodub, A. N.; William, W. A.; O'Reilly, E. M.; Von Hoff, D. D.; Goldenberg, D. M.
Abstract Title: Final results of a randomized phase 1b study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies
Meeting Title: American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer: Innovations in Research and Treatment
Journal Title: Cancer Research
Volume: 75
Issue: 13 Suppl.
Meeting Dates: 2014 May 18-21
Meeting Location: New Orleans, LA
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2015-07-01
Language: English
ACCESSION: WOS:000371263900162
DOI: 10.1158/1538-7445.panca2014-b98
PROVIDER: wos
Notes: Meeting Abstract: B98 -- Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Maeve Aine Lowery
    133 Lowery
  2. Eileen O'Reilly
    780 O'Reilly